Benzinga··Mohd HaiderOnconetix Surges 23% on Proclarix Cancer Test Validation, But Stock Down 99% Annually
Biotech firm $ONCO jumped 23.65% after-hours on clinical progress for prostate cancer blood test, despite 99% annual decline.
LHONCObiotechafter-hours trading